More and more breast cancer treatment options seem to become available these days. Check out the latest reports about this new discovery below.
Triple-negative breast cancer treatment
Breast cancer is a prevalent and life-threatening disease that affects women worldwide. Among the different types of breast cancer, triple-negative breast cancer (TNBC) is considered the most dangerous subtype.
TNBC is difficult to treat since it doesn’t respond to hormone therapy, and it can lead to the development of drug resistance, which ultimately results in poor therapeutic effects.
Recent studies have revealed that combining radiotherapy with immunotherapy can result in a synergistic effect, improving the therapeutic outcome of in situ triple-negative breast cancer (TNBC).
This innovative approach can not only improve the therapeutic effect of TNBC but also stimulate a potent abscopal effect of radiotherapy.
The abscopal effect is the phenomenon where radiation therapy not only destroys cancer cells in the targeted region but also activates the immune system to attack cancer cells in other parts of the body.
Combining therapies is a highly effective approach that can eliminate tumor cells from metastatic tumors and prevent tumor recurrence, making it a promising treatment option for triple-negative breast cancer (TNBC) patients.
It is also important that we mention the fact that the abscopal effect is a game-changer that can help treat other types of cancer, paving the way for new cancer treatment methods.
Although preclinical studies have highlighted some issues with radioimmunotherapy, such as toxic and side effects of drugs and asynchronous administration schemes, the increasing use of nanobiotechnology in tumor therapy opens up new horizons for research.
There is growing interest in nanoparticles, including inorganic and organic nanoparticles, as well as nanoparticle-hydrogel complexes, in radioimmunotherapy, which is a positive development in cancer research.
Experts’ review briefly summarizes the clinical treatment methods for TNBC and the nanobiotechnology used in preclinical studies of TNBC radioimmunotherapy.
This technology mainly focuses on locally controlled release of drugs, enhanced radiosensitization, and avoiding systemic toxicity.
However, further studies are necessary to improve the convenience and effectiveness of the treatment and explore new options for the clinical treatment of TNBC. We suggest that you check out the complete study and its results on the official page.
